Open access
Open access
Powered by Google Translator Translator

Chest Medicine

AstraZeneca bosses warn against rush for boosters – “giving the most vulnerable, who may not have built up a full immune response from the first two, a third, top-up dose is “sensible”. But any decision to give a third, booster jab “to large swathes of the population”, to extend their protection from the first two, must be based on clinical data”.

9 Sep, 2021 | 09:59h | UTC

AstraZeneca bosses warn against rush for boosters – BBC

 

Commentary on Twitter (thread – click for more)

 

Perspective | The plan to stop every respiratory virus at once – “The benefits of ventilation reach far beyond the coronavirus. What if we stop taking colds and flus for granted, too?”

9 Sep, 2021 | 09:54h | UTC

The Plan to Stop Every Respiratory Virus at Once – The Atlantic

Related:

Recommendations for ventilation of indoor spaces to reduce COVID-19 transmission.

We studied how to reduce airborne COVID spread in hospitals. Here’s what we learnt.

Report: Improved ventilation essential to safe use of buildings and public spaces, say leading engineers.

WHO: Roadmap to improve and ensure good indoor ventilation in the context of COVID-19

CDC releases new ventilation guidelines for indoor environments to reduce Covid-19 risk

Guidance: Using Ventilation and filtration to reduce aerosol transmission of COVID-19 in long-term care homes

 

A large observational study suggests eating a plant-rich diet could reduce the risk of developing severe COVID-19.

9 Sep, 2021 | 09:51h | UTC

Eating a plant rich diet reduces risk of developing COVID-19 – King’s College London

Original study: Diet quality and risk and severity of COVID-19: a prospective cohort study – Gut

 

RCT: No benefit from Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis.

9 Sep, 2021 | 08:59h | UTC

Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)

 

Spread of Delta SARS-CoV-2 variant driven by a combination of immune escape and increased infectivity.

7 Sep, 2021 | 21:49h | UTC

News release: Spread of Delta SARS-CoV-2 variant driven by combination of immune escape and increased infectivity – University of Cambridge

Original article: SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion – Nature

 

Cochrane review: evidence is insufficient to draw meaningful conclusions if SARS‐CoV‐2-specific monoclonal antibodies are effective in the treatment of COVID-19.

7 Sep, 2021 | 21:51h | UTC

Summary: Are laboratory-made, COVID-19-specific monoclonal antibodies an effective treatment for COVID-19? – Cochrane Library

Original review: SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 – Cochrane Library

 

[Preprint] M-A of 12.011.447 individuals finds individuals previously infected with SARS-CoV-2 had an 81% reduction in odds of a reinfection.

7 Sep, 2021 | 21:42h | UTC

The prevalence of adaptive immunity to COVID-19 and reinfection after recovery, a comprehensive systematic review and meta-analysis of 12 011 447 individuals – medRxiv

 

Commentary on Twitter

 

Supplement: Current Issues in Venous Thromboembolism.

7 Sep, 2021 | 21:36h | UTC

Homepage: Current Issues in Venous Thromboembolism – Postgraduate Medicine

Editorial: Current issues in venous thromboembolism

A review of upper extremity deep vein thrombosis

Outpatient treatment of emergency department patients diagnosed with venous thromboembolism

Venous thromboembolism prophylaxis in high-risk orthopedic and cancer surgery

Prophylaxis and treatment of COVID-19 related venous thromboembolism

Challenges in the diagnostic approach of suspected pulmonary embolism in COVID-19 patients

Catheter-directed thrombolysis and mechanical intervention in deep venous thrombosis: what is the status after the ATTRACT trial?

Post-hospital discharge venous thromboembolism prophylaxis in medically ill patients

Radiologic mimics of pulmonary embolism

A comprehensive review of DOACs for cancer associated VTE prophylaxis or treatment

 

The Lancet Series: Interstitial Lung Disease 2021.

7 Sep, 2021 | 21:37h | UTC

Homepage: Interstitial Lung Disease 2021 (free registration required for all articles)

Disease pathology in fibrotic interstitial lung disease: is it all about usual interstitial pneumonia?

Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities

Treatment of fibrotic interstitial lung disease: current approaches and future directions

Interstitial lung diseases: quo vadis?

Moving beyond usual interstitial pneumonia to define progressive fibrotic interstitial lung disease

 

Commentary on Twitter (thread – click for more)

 

Isn’t it time to abandon ARDS? The COVID-19 lesson.

7 Sep, 2021 | 21:34h | UTC

Isn’t it time to abandon ARDS? The COVID-19 lesson – Critical Care

 

Commentary on Twitter

 

Extended intervals and extra doses of the AstraZeneca vaccine are associated with increased immunogenicity.

7 Sep, 2021 | 10:56h | UTC

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) – The Lancet

Invited commentary: Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine

 

Commentaries on Twitter

(thread – click for more)

(thread – click for more)

 

[Preprint] Large cohort study in Brazil showed AstraZeneca vaccine had high overall effectiveness against severe disease to individuals up to 89 years of age. In comparison, CoronaVac had high overall effectiveness against severe disease in individuals up to 79 years.

7 Sep, 2021 | 10:54h | UTC

Influence of age on the effectiveness and duration of protection in Vaxzevria and CoronaVac vaccines – medRxiv

 

Annual Update in Intensive Care and Emergency Medicine 2021 – Covid articles.

7 Sep, 2021 | 10:50h | UTC

Secondary infections in critically ill patients with COVID-19

Tracheostomy for COVID-19: evolving best practice

See also: Non-Covid articles

 

Opinion | Video: Immunity is the only way through a pandemic (w/Dr. Monica Gandhi).

7 Sep, 2021 | 10:45h | UTC

Immunity Is The Only Way Through A Pandemic (w/Dr. Monica Gandhi) – ZDoggMD

 

More data showing increased risk of hospitalization with SARS-CoV-2 delta variant.

6 Sep, 2021 | 11:12h | UTC

Hospitalisation associated with SARS-CoV-2 delta variant in Denmark – The Lancet Infectious Diseases

Related study: Cohort study: Patients with Covid-19 infected with the Delta variant are twice as likely to need hospital admission or emergency care attendance.

 

The resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce; vaccine effectiveness against infection was reduced from above 90% from March through June to 65% in July.

6 Sep, 2021 | 11:09h | UTC

Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce – New England Journal of Medicine

Related:

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

Study shows AstraZeneca and Pfizer vaccines are effective against Delta variant, but both doses are needed.

 

Commentary on Twitter (thread – click for more)

 

RCT: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels.

6 Sep, 2021 | 11:11h | UTC

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial – Nature Medicine

 

Commentary on Twitter

 

Large surveillance study finds severe adverse events after COVID-19 mRNA vaccination are rare.

6 Sep, 2021 | 11:02h | UTC

Surveillance for Adverse Events After COVID-19 mRNA Vaccination – JAMA

Editorial: Safety Surveillance of COVID-19 mRNA Vaccines Through the Vaccine Safety Datalink – JAMA

Commentaries:

mRNA COVID vaccines not tied to serious side effects – CIDRAP

Researchers find no serious health effects linked to mRNA COVID-19 vaccines – News Medical

 

Commentary on Twitter

 

Interactive infographic showing the effects of Delta: How coronavirus spreads through a population and how we can beat it.

6 Sep, 2021 | 10:59h | UTC

How coronavirus spreads through a population and how we can beat it – The Guardian

 

Double vaccination halves risk of Long COVID.

3 Sep, 2021 | 10:29h | UTC

News release: Double vaccination halves risk of Long COVID – King’s College London

Original study: Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study – The Lancet Infectious Diseases

Commentaries:

Largest study of its kind finds face masks reduce COVID-19 – University of California – Berkeley

Study: Vaccines slash long-haul COVID, hospital rates – CIDRAP

Vaccination reduces risk of long Covid, even when people are infected, U.K. study indicates – STAT

Being fully vaccinated reduces odds of long-term Covid-19 symptoms by half, UK study suggests – CNN

Coronavirus vaccines cut risk of long Covid, study finds – BBC

Related: M-A: More than 50 long-term effects of COVID-19.

 

Commentary on Twitter

 

WHO says it is monitoring a new Covid variant called ‘mu’.

3 Sep, 2021 | 10:21h | UTC

WHO says it is monitoring a new Covid variant called ‘mu’ – CNBC

See also:

What’s the Mu variant? And will we keep seeing more concerning variants? – The Conversation

WHO monitoring new coronavirus variant named ‘Mu’ – France 24

New ‘mu’ coronavirus variant could escape vaccine-induced immunity, WHO says – LiveScience

WHO monitoring new coronavirus variant named Mu – The Guardian

 

[Preprint] Largest study of masks yet details their importance in fighting Covid-19.

3 Sep, 2021 | 10:30h | UTC

Largest study of masks yet details their importance in fighting Covid-19 – NBC News

Original study: The Impact of Community Masking on COVID-19: A Cluster-Randomized Trial in Bangladesh – Innovations for Poverty Action

See also: A Study In Bangladesh Tripled The Rate Of Mask-Wearing. Can It Help In The U.S.? – NPR

 

Commentaries on Twitter (thread – click for more)

(thread from the author – click for more)

 

EU agency says to focus on vaccines first not booster shots.

3 Sep, 2021 | 10:34h | UTC

EU agency says to focus on vaccines first not booster shots – Associated Press

See also: European officials say COVID-19 booster isn’t urgent – CIDRAP

 

RCT: Baricitinib reduced mortality in hospitalized adults with COVID-19.

2 Sep, 2021 | 10:17h | UTC

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial – The Lancet Respiratory Medicine

Commentaries:

Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial – The Lancet Respiratory Medicine

Rheumatoid Arthritis Drug Combined with Standard of Care May Help Reduce Mortality for Hospitalized COVID-19 Patients – Vanderbilt University Medical Center

 

Commentaries on Twitter

(thread – click for more)

 

Review | COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses.

2 Sep, 2021 | 10:06h | UTC

COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses – The Lancet Rheumatology

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.